GD2 targeting CAR T cells for neuroblastoma
Treatment of neuroblastoma is a significant clinical unmet need in paediatric oncology epitomised by high-risk disease in which relapse is common and outcomes for children with relapse or primary refractory disease are typically poor, with 4-year progression-free survival for relapse/refractory dise...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | EJC Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X24000382 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061349510447104 |
|---|---|
| author | John Anderson Giuseppe Barone Alexandra Zehner |
| author_facet | John Anderson Giuseppe Barone Alexandra Zehner |
| author_sort | John Anderson |
| collection | DOAJ |
| description | Treatment of neuroblastoma is a significant clinical unmet need in paediatric oncology epitomised by high-risk disease in which relapse is common and outcomes for children with relapse or primary refractory disease are typically poor, with 4-year progression-free survival for relapse/refractory disease of 6 %. Immunotherapy targeting disialoganglioside GD2 using monoclonal antibodies (mAb) has become a component of standard of care treatment in neuroblastoma following published studies that have demonstrated clinical activity and survival benefit associated with this treatment. Hence a number of research groups have developed and clinically evaluated chimeric antigen receptor gene modified T cells (CAR-T cells) targeting GD2 in patients with relapsed and refractory neuroblastoma. Preclinical and clinical results using a range of receptor technologies and immune effectors have demonstrated the basic safety and feasibility of this approach, progressing into clinical data exhibiting promise for sustained patient benefit. |
| format | Article |
| id | doaj-art-6c9c58e7e9844cc68df7e0d24ad20f8a |
| institution | DOAJ |
| issn | 2772-610X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Paediatric Oncology |
| spelling | doaj-art-6c9c58e7e9844cc68df7e0d24ad20f8a2025-08-20T02:50:16ZengElsevierEJC Paediatric Oncology2772-610X2024-12-01410017910.1016/j.ejcped.2024.100179GD2 targeting CAR T cells for neuroblastomaJohn Anderson0Giuseppe Barone1Alexandra Zehner2UCL Great Ormond Street Institute of Child Health, University College London, UK; Department of Oncology, Great Ormond Street Hospital for Children, London, UK; Corresponding author at: UCL Great Ormond Street Institute of Child Health, University College London, UKDepartment of Oncology, Great Ormond Street Hospital for Children, London, UKUCL Great Ormond Street Institute of Child Health, University College London, UKTreatment of neuroblastoma is a significant clinical unmet need in paediatric oncology epitomised by high-risk disease in which relapse is common and outcomes for children with relapse or primary refractory disease are typically poor, with 4-year progression-free survival for relapse/refractory disease of 6 %. Immunotherapy targeting disialoganglioside GD2 using monoclonal antibodies (mAb) has become a component of standard of care treatment in neuroblastoma following published studies that have demonstrated clinical activity and survival benefit associated with this treatment. Hence a number of research groups have developed and clinically evaluated chimeric antigen receptor gene modified T cells (CAR-T cells) targeting GD2 in patients with relapsed and refractory neuroblastoma. Preclinical and clinical results using a range of receptor technologies and immune effectors have demonstrated the basic safety and feasibility of this approach, progressing into clinical data exhibiting promise for sustained patient benefit.http://www.sciencedirect.com/science/article/pii/S2772610X24000382NeuroblastomaCAR-T cells GD2Disialoganglioside |
| spellingShingle | John Anderson Giuseppe Barone Alexandra Zehner GD2 targeting CAR T cells for neuroblastoma EJC Paediatric Oncology Neuroblastoma CAR-T cells GD2 Disialoganglioside |
| title | GD2 targeting CAR T cells for neuroblastoma |
| title_full | GD2 targeting CAR T cells for neuroblastoma |
| title_fullStr | GD2 targeting CAR T cells for neuroblastoma |
| title_full_unstemmed | GD2 targeting CAR T cells for neuroblastoma |
| title_short | GD2 targeting CAR T cells for neuroblastoma |
| title_sort | gd2 targeting car t cells for neuroblastoma |
| topic | Neuroblastoma CAR-T cells GD2 Disialoganglioside |
| url | http://www.sciencedirect.com/science/article/pii/S2772610X24000382 |
| work_keys_str_mv | AT johnanderson gd2targetingcartcellsforneuroblastoma AT giuseppebarone gd2targetingcartcellsforneuroblastoma AT alexandrazehner gd2targetingcartcellsforneuroblastoma |